Report

The global needle free injection system market is projected to witness a CAGR of 15.1% during the forecast period 2024-2031, growing from USD 150.86 million in 2023 to USD 464.7 million in 2031. The global needle free injection system is being driven by factors such as the increasing preference of patients towards self-administration, rising hospitalization rates, clinical advantages offered by needle free injection systems as compared to conventional needles, technological advancements, increasing prevalence of chronic diseases, and growing emphasis towards patient safety and comfort. Needle free injectors, also known as jet injectors, are medical devices that deliver medication through the skin by using high pressure stream of fluid without the need for a needle. The main purpose of developing needle free injection system was to reduce needlestick injuries, cross-contamination, and needle reuse. Needle-free injectors have evolved over the years and are being recommended by the World Health Organization to address polio vaccine supply shortages. Needle free injectors are ideal for personal use to self-administer insulin, hormones, vitamin B-12, and other liquid injectable grade medications.
Microneedles are becoming more and more popular because of their ability to enter the human body and skin effectively without causing drug degradation. Their easy-to-operate microscale form factor and painless drug delivery are additional factors driving their demand among the general population.
In June 2023, PharmaJet announced that two new COVID-19 vaccines would only be administered intradermally using its Tropis system. The precision delivery systems developed by PharmaJet, based in Golden, Colorado, solve the problems associated with the delivery of nucleic acid vaccines. The first plasmid DNA COVID-19 vaccine from Zydus Lifesciences can now be delivered using its Tropis system. According to PharmaJet, Tropis has already completed millions of injections as part of several global immunization campaigns. Data consistently showed that nucleic acid vaccines and treatments had higher immunogenicity than those administered by needle and syringe or electroporation.
Increasing Prevalence of Infectious Diseases and Diabetes
The increasing prevalence of diabetes and other infectious diseases is significantly driving the global needle free injection system market. The need for effective and patient-friendly drug or vaccine delivery methods is growing due to the increasing prevalence of diabetes and infectious diseases. By reducing the discomfort associated with infections, needle-free injectors present a convincing alternative that enhances patient adherence to treatment protocols. Needle free injections are becoming more and more popular due to the rise in chronic illnesses like diabetes and autoimmune diseases, which makes needle-free alternatives a painless choice. Additionally, the importance of needle-free technologies and solutions has become more widely recognized due to the increasing risk of transmission through needle-based injections. Since 2021, there has been a significant increase in different infectious diseases, such as TB, influenza, diphtheria, pneumonia, mumps, and malaria, accounting for 20.6%, 354.3%, 220.5%, 2656.1%, and 990.3%, respectively.
Increasing Preference of Patients Towards Self-Administration
Patient preferences for self-administration of medications have significantly changed with the introduction of novel needle-free injection systems. This trend arises from several factors that improve patients' overall wellbeing, safety, and convenience. By eliminating the possibility of needlestick injuries, needle-free injectors reduce the possible risks associated with using traditional needles. By providing painless drug delivery, they improve patient satisfaction and comfort during the administration of medications. Compared to invasive drug delivery systems, needle-free injectors allow for faster drug delivery, which improves bioavailability and efficacy. The need for accessible and user-friendly medication administration methods will grow as the world's population ages and the prevalence of chronic illnesses rises. Needle-free injectors have the potential to completely transform medicine administration, which will ultimately benefit patients and healthcare professionals by providing an effective solution to the problems associated with traditional needle injections.
According to estimates from the Centers for Disease Control and Prevention (CDC), more than 3,85,000 hospital-based workers face needlestick injuries annually. Similar injuries also happen in private homes, clinics, emergency rooms, and other healthcare settings. Sharp injuries have been linked to the transmission of over 20 different pathogens, but they are mainly linked to the transmission of hepatitis B, hepatitis C, and human immunodeficiency virus (HIV).
Technological Advancements
Needle free injectors are a groundbreaking advancement in the field of medical devices and drug/vaccine delivery systems. It offers a patient-friendly and efficient alternative to traditional needle-based injections. The most recent advancement in this field is increasing focus on enhancing dosage control, reducing discomfort, and increasing accuracy. One noteworthy advancement is the use of liquid streams accelerated to high velocities to pierce the skin in place of traditional needles. Personalized healthcare has improved with the advent of smart needle-free injectors that are outfitted with cutting-edge sensors and connectivity features to facilitate real-time monitoring and data collection.
In January 2023, the FDA approved the DropSafe Sicura passive safety needle, an innovative injection needle with a fully passive mechanism that can be used for the intramuscular and subcutaneous injection of vaccines and other drugs, according to a press release from MTD Group's affiliate Pikdare S.p.A. A transparent shield guards the needle and locks automatically after injection, eliminating the need for the healthcare professionals to perform a post-injection incremental activation step.
North America Holds the Largest Share in the Market
North America accounts for more than 50% of the global needle free infection system market. North America's dominance can be attributed to several factors such as the presence of major players, innovative technologies, and a fast regulatory process by the FDA. The region offers a strong healthcare infrastructure and a high degree of awareness about the advantages of needle-free injection technologies among the public and healthcare professionals. In North America, the prevalence of diabetes and infectious diseases is comparatively high, which generates a significant demand for advanced drug delivery systems. Significant market players have a strong presence in the USA, Canada, Mexico, and global markets. The regulatory framework is favorable, encouraging innovation and the adoption of new medical technologies. The United States has a hassle-free approval and commercialization process for needle-free injection systems due to the FDA's support.
In June 2022, Berkeley-based NovaXS Biotech Corporation, a medical device company, unveiled its smart, needle-free drug delivery device. With its patent-pending Telosis technology, NovaXS will be able to analyze injection data and provide a precise, needle-free medication stream in just 0.3 seconds, enabling more informed health decisions. In a press release, the company stated that its technology is the first of its kind in the world for remote medication delivery and self-administration monitoring, providing a simple and painless substitute.
Fillable Needle Free Injectors Hold the Largest Share Globally
Fillable injectors account for the largest share of the global needle free injection system market. Fillable needle-free injectors offer several advantages over prefilled needle-free injectors. One key advantage is the ability to customize dosages by allowing on-demand filling of the injector device with the desired medication, providing flexibility in drug administration. Fillable injectors also offer the potential for targeted drug delivery, ensuring precise dosages tailored to individual patient needs. Additionally, fillable injectors can accommodate a variety of medications, making them versatile for different treatment regimens. In contrast, prefilled injectors come pre-loaded with a specific dosage, limiting the flexibility in drug administration and customization compared to fillable injectors. Moreover, fillable injectors can be more cost-effective as they allow for the use of generic medications or multiple doses from a single vial, reducing overall treatment costs.
Future Market Scenario (2024-2031F)
The future market scenario for the global needle free injection system market is poised for substantial growth, driven by new technologies. There is an increasing demand for painless drug delivery methods, leading to the adoption of needle-free injectors as a patient-friendly alternative. Advancements in microfluidics and nanotechnology have paved the way for more precise and efficient drug administration. Integration of smart features, such as connectivity with phones and personalized dosing, is becoming a prominent trend. The market is also witnessing the development of wearable injectors that offer convenience and continuous monitoring. Microjet and spring jets are gaining popularity for their effectiveness and reduced discomfort.
Key Players Landscape and Outlook
The global needle free injection system market is characterized by a competitive landscape with key players driving innovation and market expansion. The global market is dominated by players such as Pharmajet Inc., Crossject SA, Medical International Technology Inc., Micropoint Technologies Pte Ltd, Antres Pharma Inc., Penjet Corporation, NuGen Medical Devices Inc., Ferring International Center SA, Portal Instruments Inc., and Bioject Medical Technologies Inc. These market players are investing in R&D to improve product efficacy, patient comfort and dosage precision. Partnerships and collaborations between medical device and pharmaceutical companies for the integration of needle free injection systems with specific medications are becoming common, further strengthening the presence of these market players.
In May 2022, the world's first disposable range of needle-free livestock vaccination devices was launched by Pulse NeedleFree Systems, the top provider of needle-free delivery technologies to the animal health sector. As a fixed dose device, the Pulse FX doesn't need to have any parts replaced or maintenance done. Dosage volumes ranging from 0.2 ml to 2.0 ml are available, with options for stationery or hand-held delivery.